These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Beyond Bayh-Dole and the Lambert Review: an initial product development and transaction model for the interface between universities and business. Fernandes M; Miska D Biotechnol Genet Eng Rev; 2004; 21():249-76. PubMed ID: 17017036 [No Abstract] [Full Text] [Related]
5. Bayh-Dole: if we knew then what we know now. Boettiger S; Bennett AB Nat Biotechnol; 2006 Mar; 24(3):320-3. PubMed ID: 16525405 [No Abstract] [Full Text] [Related]
6. Technology transfer at US universities: seeking public benefit from the results of basic research. Goodwin CD Technol Health Care; 1996 Sep; 4(3):323-30. PubMed ID: 8931243 [TBL] [Abstract][Full Text] [Related]
8. Columbia University's Axel patents: technology transfer and implications for the Bayh-Dole Act. Colaianni A; Cook-Deegan R Milbank Q; 2009 Sep; 87(3):683-715. PubMed ID: 19751286 [TBL] [Abstract][Full Text] [Related]
9. Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh-Dole Act. Silva PJ; Ramos KS Acad Med; 2018 Aug; 93(8):1135-1141. PubMed ID: 29668523 [TBL] [Abstract][Full Text] [Related]
10. The Bayh-Dole Act, a lion without claws. Feldman AM Clin Transl Sci; 2015 Feb; 8(1):3-4. PubMed ID: 25675969 [No Abstract] [Full Text] [Related]
11. Bayh-Dole: almost 25. Kennedy D Science; 2005 Mar; 307(5714):1375. PubMed ID: 15746390 [No Abstract] [Full Text] [Related]
12. Why did universities start patenting? Institution-building and the road to the Bayh-Dole Act. Berman EP Soc Stud Sci; 2008 Dec; 38(6):835-71. PubMed ID: 19227798 [TBL] [Abstract][Full Text] [Related]
13. Is Bayh-Dole good for developing countries? Lessons from the US experience. So AD; Sampat BN; Rai AK; Cook-Deegan R; Reichman JH; Weissman R; Kapczynski A PLoS Biol; 2008 Oct; 6(10):e262. PubMed ID: 18959484 [TBL] [Abstract][Full Text] [Related]
14. Patents, profits, and the American people--the Bayh-Dole Act of 1980. Markel H N Engl J Med; 2013 Aug; 369(9):794-6. PubMed ID: 23984726 [No Abstract] [Full Text] [Related]
15. Global biotech expansion taking cues from Bayh-Dole. Howard K Nat Biotechnol; 2004 Jul; 22(7):919-20. PubMed ID: 15259190 [No Abstract] [Full Text] [Related]
16. Patent and license pearls and pitfalls for taking an idea to the marketplace. Mukharji I J Investig Med; 2011 Jun; 59(5):758-61. PubMed ID: 21441827 [TBL] [Abstract][Full Text] [Related]
17. March-in rights under the Bayh-Dole Act: the NIH's paper tiger? O'Brien W Seton Hall Law Rev; 2013 Nov; 43(4):1403-32. PubMed ID: 24308083 [No Abstract] [Full Text] [Related]
18. Who owns federally funded research? The Supreme court and the Bayh-Dole act. Kesselheim AS; Rajkumar R N Engl J Med; 2011 Sep; 365(13):1167-9. PubMed ID: 21879888 [No Abstract] [Full Text] [Related]
19. The demise of Bayh-Dole protections against the Pharmaceutical Industry's abuses of government-funded inventions. Schofield AR J Law Med Ethics; 2004; 32(4):777-83. PubMed ID: 15807367 [No Abstract] [Full Text] [Related]
20. The Bayh-Dole Act: a model for promoting research translation? Loewenberg S Mol Oncol; 2009 Apr; 3(2):91-3. PubMed ID: 19383372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]